Nonirritating Concentrations of midazolam, ketamine, and ondansetron

Overview

About this study

The purpose of this study is to determine the maximal nonirritating concentrations of midazolam, ketamine, and ondansetron.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Healthy adult volunteers
  • Not have a history of an adverse reactions to midazolam, ketamine or ondansetron
  • Ability to understand study procedures and to comply with them for the entire length of the study.
  • Contraception is not necessary, and we will include women of reproductive capability.

Exclusion Criteria: 

  • Unstable patients
  • History of any adverse reaction (allergy or sensitivity) to midazolam, ketamine or ondansetron. 
  • Pediatric patients
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/17/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Alexei Gonzalez Estrada, M.D.

Contact us for the latest status

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available